Compass Therapeutics (CMPX) Equity Ratio (2018 - 2026)

Compass Therapeutics' Equity Ratio history runs 9 years deep, the most recent figure standing at 0.91 for Q1 2026.

• In Q1 2026, Equity Ratio rose 8.34% year-over-year to 0.91; the TTM figure through Mar 2026 stood at 0.91 (up 8.34% YoY), while the FY2025 annual figure was 0.9, changed 0.47% from the prior year.
• Equity Ratio came in at 0.91 for Q1 2026 at Compass Therapeutics, up from 0.9 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.97 in Q1 2024 to a low of 0.8 in Q2 2025.
• A 5-year average of 0.91 and a median of 0.91 in 2022 frame the typical range for Equity Ratio.
• Across the five-year window, Equity Ratio jumped 32.7% in 2022 and fell 14.93% in 2025, its largest moves.
• Compass Therapeutics' Equity Ratio stood at 0.91 in 2022, then gained by 4.07% to 0.95 in 2023, then dropped by 5.8% to 0.89 in 2024, then grew by 0.47% to 0.9 in 2025, then rose by 1.42% to 0.91 in 2026.
• According to Business Quant data, Equity Ratio over the past three periods registered 0.91, 0.9, and 0.91 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison